Inserm Transfert SA / ILiAD Biotechnologies LLC / IPL / Inserm Transfert Initiative / ie/ About ILiAD Biotechnologies LLC / Institut Pasteur de Lille / Walter Greenblatt & Associates / Open Innovation / /
Country
France / United States / /
Currency
EUR / / /
Event
M&A / Business Partnership / /
Facility
National University of Singapore / Medical Research Institute / French National Institute of Health / University Presidents / University of Ireland Maynooth / University Hospital Centres / Pasteur Institute / National University of Ireland Maynooth / /
IndustryTerm
biotechnology / pharmaceutical industry / technology institute / private subsidiary / vaccine technology / investment bank / potential products / pertussis vaccine technology / treatment of human disease / technology transfer / /
National Alliance / Institut Pasteur de Lille Enter Scientific Collaboration / Center for Infection and Immunity / National University of Singapore / French Ministry of Higher Education and Research / National University of Ireland Maynooth / French National Institute of Health / Institut Pasteur de Lille / Pasteur Institute / French National Health and Medical Research Institute / Ministry of Health / Medical Research / /
Person
Keith Rubin / Stéphane Thumelin / Camille Locht / Augustin Godard / Ken Solovay / / /
Position
Director Business Development / Licensing / VP / Céline Cortot Communications Director / exclusive financial advisor / head / Manager Institut Pasteur de Lille yves.lemoine@pasteur-lille.fr / CEO / Director Inserm Transfert Celine.cortot@insermtransfert.fr Communications / Professor / EVP / Private / /
Press Release ILiAD Biotechnologies, Inserm and Inserm Transfert SA, and Institut Pasteur de Lille Enter Scientific Collaboration and Worldwide License Agreements for Vaccine Technology NEW YORK (USA), PARIS and LILLE (